β-amyloid immunization approaches for Alzheimer's disease

Drug Development Research

Volumn 56, Issue 2, 2002, Pages 150-162

  Imbimbo, Bruno P ^a  

^a Research and Development Department   (Italy)

Author keywords

amyloid; Alzheimer's disease; AN 1792; Immunization; Vaccination

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; FREUND ADJUVANT; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; QS 21;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ASTROCYTOSIS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DYSTROPHY; ENCEPHALITIS; HUMAN; IMMUNIZATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE; VACCINATION;

EID: 0036595125     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10070     Document Type: Review

References (75)

1. Vaccines and vaccination
2. Behavioral assessment of Alzheimer's transgenic mice following long-term Aβ vaccination: Task specificity and correlations between Aβ deposition and spatial memory
3. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy
4. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
5. Interaction of Hsp 70 with newly synthesized proteins: Implications for protein folding and assembly
6. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo
7. Encapsulation in biodegradable micro particles enhances serum antibody response to parenterally-delivered β-amyloid in mice
8. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
9. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
10. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
11. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition
12. Challenging the cholinergic hypothesis in Alzheimer disease
13. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
14. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated P-amyloid 1-42 peptide
15. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
16. β-amyloid protein aggregation: Its implication in the physiopathology of Alzheimer's disease
17. Deaths attributable to Alzheimer's disease in the United States
18. Characterization of cholylleu-val-phe-phe-ala-OH as an inhibitor of amyloid β-peptide polymerization
19. N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies
20. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration
21. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
22. Structure-based design: Potent inhibitors of human brain memapsin 2 (β-secretase)
23. Immunization with β-amyloid: Could T-cell activation have a harmful effect?
24. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
25. Effects of a peripheral anti-Aβ antibody on plasma and CNS Aβ clearance
26. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
27. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
28. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
29. Heat-shocked neuronal PC12 cells reveal Alzheimer's disease-associated alterations in amyloid precursor protein and tau
30. QS-21 and QS-7: Purified saponin adjuvants
31. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?
32. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins
33. Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies
34. Improvement in intranasal Aβ immunization in mice
35. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice
36. Alzheimer's disease care: Costs and potential savings
37. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
38. Aβ-42 deposition precedes other changes in PS-1 Alzheimer's disease
39. Transfected human B cells: A new model to study the functional and immunostimulatory consequences of APP production
40. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
41. Immune responses to stress proteins: Applications to infectious disease and cancer
42. Immune hyporesponsiveness to amyloid β-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease
43. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
44. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
45. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline
46. A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice
47. Mutant presenilin 2 transgenic mouse: Effect on an age-dependent increase of amyloid β-protein 42 in the brain
48. Increased synthesis and accumulation of heat shock 70 proteins in Alzheimer's disease
49. Amyloid β peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier
50. Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia
51. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
52. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
53. Economic considerations in the treatment and management of Alzheimer's disease
54. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice
55. Safety of potential vaccines for Alzheimer's disease
56. Towards diagnosis and treatment of Alzheimer's disease
57. Disaggregation of Alzheimer β-amyloid by site-directed mAb
58. Structural determinants of the Alzheimer's amyloid β-peptide
59. Fibrillogenesis of synthetic amyloid-β peptides is dependent on their initial secondary structure
60. Alzheimer's disease. Antibody clears senile plaques
61. An increased percentage of long amyloid β protein secreted by familial amyloid beta protein precursor (βAPP717) mutants
62. AN-1792 (Elan)
63. Immune response against the murine mdri protein induced by vaccination with synthetic lipopeptides in liposomes
64. Characterization of murine immunoglobulin G antibodies against human amyloid-β-1-42
65. Design of substrate-based inhibitors of human β-secretase
66. β-amyloid peptide vaccination results in marked changes in serum and brain Aβ levels in APPswe/PS1deltaE9 mice, as detected by SELDI-TOF-based protein chip(R) technology
67. Soluble oligomers of β-amyloid(1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus
68. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
69. Number of Aβ inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels
70. γ-secretase inhibitors as molecular probes of presenilin function
71. Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease